Incretins: all 1,182 studies that test it
Page 7 of 12. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver TransplantationCompletedNCT05042505Not applicable
- Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and AcarboseCompletedNCT05035849Not applicable
- Human Bioequivalence Test of Liraglutide InjectionCompletedNCT05029076Phase 1
- Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 DiabetesCompletedNCT04916093Phase 4
- A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With LiraglutideCompletedNCT04903509Phase 1
- Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)CompletedNCT04897802Phase 4
- Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese SubjectsCompletedNCT04877106Phase 1
- The Effect and the Pharmacogenomics Study of Liraglutide in Obese PatientsWithdrawnNCT04839237Phase 2
- Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?CompletedNCT04781998Phase 4
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityActive, not recruitingNCT04775082Phase 3
- Liraglutide Plus Megestrol Acetate in Endometrial Atypical HyperplasiaWithdrawnNCT04683237Phase 2/3
- Targeting Beta-cell Failure in Lean Patients With Type 2 DiabetesCompletedNCT04657939Phase 4
- Liraglutide for Low-responders After Bariatric SurgeryWithdrawnNCT04643301Not applicable
- The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight PatientsCompletedNCT04605861Phase 3
- Study of the Cardiometabolic Effects of Obesity PharmacotherapyStatus unknownNCT04575194Phase 4
- Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19CompletedNCT04542213Phase 3
- Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" TrialCompletedNCT04535960Phase 2
- Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis PatientsStatus unknownNCT04529278Phase 2
- Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbiditiesStatus unknownNCT04525300Phase 3
- Tubular Markers in Response to Saxagliptin TherapyCompletedNCT04521049Phase 4
- Brain Activation and Satiety in Children 2Active, not recruitingNCT04520490Phase 3
- Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbiditiesStatus unknownNCT04487743Phase 3
- Glimepiride, Alogliptin and Alogliptin+Pioglitazone CombinationStatus unknownNCT04470310Phase 4
- Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host DiseaseStatus unknownNCT04448587Phase 2
- Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist StudyCompletedNCT04409795Phase 2/3
- Anti-inflammatory Status in DM2 Treated PatientsStatus unknownNCT04392557Phase 4
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19TerminatedNCT04371978Phase 3
- The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic PatientsStatus unknownNCT04365517Phase 3
- Glucagon-like Peptide-1 in Type 1 DiabetesWithdrawnNCT04355832Early Phase 1
- Effects of DPP4 Inhibition on COVID-19WithdrawnNCT04341935Phase 4
- Acute Effects of GLP-1 on Renal HemodynamicsCompletedNCT04337268Not applicable
- Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese PatientsCompletedNCT04325581Phase 3
- Liraglutide in the Prevention of Type 2 Diabetes After Gestational DiabetesCompletedNCT04324229Not applicable
- Effects of Sitagliptin in Individuals With Genetically Decreased DPP4Active, not recruitingNCT04323189Phase 4
- Exenatide Treatment in Parkinson's DiseaseStatus unknownNCT04305002Phase 2
- Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)CompletedNCT04304261Phase 3
- Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic AgentsStatus unknownNCT04287387Phase 4
- Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS PatientsStatus unknownNCT04268563Phase 1/2
- Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseCompletedNCT04232969Phase 3
- Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep ApneaCompletedNCT04186494Not applicable
- Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy VolunteersStatus unknownNCT04170790Not applicable
- Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial DiseaseStatus unknownNCT04146155Phase 4
- Clinical Study on the Improvement of Diabetic Neuropathic Pain by LiraglutideStatus unknownNCT04137328Not applicable
- Effect of Low Dose Combination of Linagliptin + Metformin to Prevent DiabetesStatus unknownNCT04134650Phase 3
- Effect of GLP-1 on Microvascular Insulin Responses in Type 1 DiabetesWithdrawnNCT04133922Early Phase 1
- Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With PrediabetesStatus unknownNCT04131582Phase 3
- Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie DietStatus unknownNCT04122716Phase 4
- Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With MetformineCompletedNCT04088461Phase 4
- Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon SecretionCompletedNCT04061473Not applicable
- Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular DiseaseWithdrawnNCT04057261Phase 3
- Effect of Liraglutide on Microbiome in ObesityStatus unknownNCT04046822Phase 4
- Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS PatientsStatus unknownNCT04029272Phase 4
- The Effect of Liraglutide on the GITStatus unknownNCT04008290Phase 4
- Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.CompletedNCT03970044Phase 4
- Treatment of Bile Acid Malabsorption With LiraglutideCompletedNCT03955575Phase 4
- Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes MellitusStatus unknownNCT03948347Not applicable
- Neuropeptide Y and Sympathovagal BalanceCompletedNCT03933787Early Phase 1
- Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 DiabetesCompletedNCT03893526Phase 4
- Liraglutide Effect in Atrial FibrillationActive, not recruitingNCT03856632Phase 4
- Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersCompletedNCT03835013Not applicable
- To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue ReactivityCompletedNCT03795701Not applicable
- Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug NaiveCompletedNCT03794336Phase 4
- Drug Interaction Study Between Dorzagliatin and SitagliptinCompletedNCT03790839Phase 1
- The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 DiabetesCompletedNCT03734718Not applicable
- The Effects of Neprilysin on Glucagon-like Peptide-1CompletedNCT03717688Phase 4
- Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.CompletedNCT03714594Phase 2
- Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes MellitusCompletedNCT03707171Phase 3
- The Use of Liraglutide in Brain DeathCompletedNCT03672812Phase 3
- Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese PatientsStatus unknownNCT03671733Phase 3
- Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal InsufficiencyCompletedNCT03667300Phase 2
- Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes MellitusCompletedNCT03659461Not applicable
- Efficacy and Safety of Empagliflozin in NODATTerminatedNCT03642184Phase 4
- Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1DCompletedNCT03632759Early Phase 1
- Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.CompletedNCT03619330Phase 4
- Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 DiabetesStatus unknownNCT03602638Phase 4
- Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 DiabetesCompletedNCT03556098Not applicable
- Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mgCompletedNCT03534310Not applicable
- The Effect of Liraglutide on Pancreatic Hormones and Its SizeCompletedNCT03520062Not applicable
- Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)WithdrawnNCT03504566Phase 4
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin TherapyCompletedNCT03499704Phase 4
- Effects of Liraglutide in Chronic Obstructive Pulmonary DiseaseCompletedNCT03466021Phase 4
- Effects of Exenatide on Motor Function and the BrainCompletedNCT03456687Phase 1
- Effect of Liraglutide on Vascular Inflammation in Type-2 DiabetesCompletedNCT03449654Phase 4
- Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 DiabetesStatus unknownNCT03444142Phase 4
- Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetESStatus unknownNCT03433248Phase 4
- The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 DiabetesStatus unknownNCT03426085Phase 2
- Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II DiabetesStatus unknownNCT03421119Phase 3
- Research of Intensive Metabolic Intervention Before Pregnancy in PCOSStatus unknownNCT03383068Phase 4
- Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)WithdrawnNCT03371862Phase 2
- DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2CompletedNCT03361098Phase 4
- The Effect of a Liraglutide on IVF in Obese PCOSCompletedNCT03353948Phase 4
- Research of Exenatide for Overweight/Obese PCOS Patients With IGRCompletedNCT03352869Phase 4
- Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 ResponseCompletedNCT03341429Phase 4
- A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin TherapyStatus unknownNCT03320031Phase 4
- A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese SubjectsCompletedNCT03292185Phase 1
- Trial of EXenatide in Acute Ischaemic StrokeStatus unknownNCT03287076Phase 2
- SGLT2i and Incretin and CRTd.CompletedNCT03282136Phase 4
- Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?CompletedNCT03232112Phase 2
- A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.CompletedNCT03169959Phase 1
- Effect of Exenatide on Cortisol SecretionCompletedNCT03160261Phase 4